VYNE THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.59 USD | +3.60% |
|
+10.21% | +11.16% |
| Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
| Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Presenter SpeechGavin Clark-Gartner (Analysts)All right. Welcome, everyone. Thanks for tuning ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.5
USD
Average target price
5.583
USD
Spread / Average Target
+123.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.16% | 35.25M | |
| +25.99% | 661B | |
| +26.74% | 566B | |
| -6.73% | 352B | |
| +19.44% | 332B | |
| +3.48% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.33% | 145B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- Transcript : VYNE Therapeutics Inc. - Special Call
